The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Gefitinib as third-line re-challenge treatment in advanced NSCLC patients with EGFR activating mutation who benefited from first-line gefitinib treatment followed by second-line chemotherapy.
 
Yong Song
No Relationships to Disclose
 
Yi-Long Wu
Honoraria - AstraZeneca; Lilly; Pfizer; Pierre Fabre; Roche; Sanofi
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Merck; Roche
Research Funding - Boehringer Ingelheim (Inst); Roche (Inst)
 
Lejie Cao
No Relationships to Disclose
 
Jianhua Chen
No Relationships to Disclose
 
Zhiyong Ma
No Relationships to Disclose
 
Jiuwei Cui
No Relationships to Disclose
 
Xin Ye
Employment - AstraZeneca
 
Jingyan Ding
Employment - AstraZeneca